Omeros (NASDAQ:OMER) Rating Increased to Hold at Zacks Investment Research
According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
Several other research analysts have also recently commented on the company. Wedbush set a $20.00 target price on Plymouth Industrial Reit and gave the stock a buy rating in a research report on Monday, May 20th. Cantor Fitzgerald reaffirmed a buy rating and issued a $71.00 target price on shares of ExlService in a research report on Monday, May 6th. HC Wainwright set a $55.00 target price on Acer Therapeutics and gave the stock a buy rating in a research report on Tuesday, May 28th. ValuEngine cut Yirendai from a sell rating to a strong sell rating in a research report on Wednesday, June 26th. Finally, BidaskClub cut Vertex Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Omeros presently has an average rating of Hold and a consensus target price of $25.80.
Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The business had revenue of $21.80 million during the quarter, compared to analysts’ expectations of $23.18 million. During the same period in the prior year, the firm earned ($0.62) earnings per share. The firm’s revenue for the quarter was up 1271.1% on a year-over-year basis. As a group, equities research analysts predict that Omeros will post -1.51 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in OMER. Rhumbline Advisers raised its stake in Omeros by 73.3% during the fourth quarter. Rhumbline Advisers now owns 72,243 shares of the biopharmaceutical company’s stock worth $805,000 after acquiring an additional 30,547 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Omeros by 31.7% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,250 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 4,150 shares in the last quarter. First Trust Advisors LP acquired a new position in Omeros during the fourth quarter worth $879,000. California Public Employees Retirement System raised its stake in Omeros by 6.7% during the fourth quarter. California Public Employees Retirement System now owns 49,310 shares of the biopharmaceutical company’s stock worth $549,000 after acquiring an additional 3,110 shares in the last quarter. Finally, BlackRock Inc. raised its stake in Omeros by 0.8% during the fourth quarter. BlackRock Inc. now owns 3,989,206 shares of the biopharmaceutical company’s stock worth $44,439,000 after acquiring an additional 31,270 shares in the last quarter. Hedge funds and other institutional investors own 52.12% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.